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Flaxseed supplementation improved insulin
resistance in obese glucose intolerant people:
a randomized crossover design
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Abstract
Background: Obesity leads to an increase in inflammation and insulin resistance. This study determined
antioxidant activity of flaxseed and its role in inflammation and insulin resistance in obese glucose intolerant
people.
Methods: Using a randomized crossover design, nine obese glucose intolerant people consumed 40 g ground
flaxseed or 40 g wheat bran daily for 12 weeks with a 4-week washout period. Plasma inflammation biomarkers
(CRP, TNF-a, and IL-6), glucose, insulin, and thiobaribituric acid reactive substance (TBARS) were measured before
and after of each supplementation.
Results: Flaxseed supplementation decreased TBARS (p = 0.0215) and HOMA-IR (p = 0.0382). Flaxseed or wheat
bran supplementation did not change plasma inflammatory biomarkers. A positive relationship was found between
TBARS and HOMA-IR (r = 0.62, p = 0.0003).
Conclusions: The results of the study weakly support that decreased insulin resistance might have been secondary
to antioxidant activity of flaxseed. However, the mechanism(s) of decreased insulin resistance by flaxseed should be
further determined using flaxseed lignan.
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Background
Obesity is a major public health problem [1]. Obesity
increases insulin resistance, reactive oxygen species
(ROS) generation and nuclear factor (NF)-B activation
[2,3]. The increase in NF-B activation leads to low
grade inflammation and contributes to the development
of diabetes [4]. Studies have reported that pro-inflam-
matory cytokines, tumor necrosis factor (TNF)-a and
interleukin (IL)-6, are associated with an increased hepa-
tic C-reactive protein (CRP) synthesis, inflammation,
and insulin resistance in humans and animals [5-14].
TNF-a has been positively related to factors associated
with metabolic syndrome, including increased triglycer-
ide concentration, blood pressure, and body mass index
(BMI) [5,10].
Antioxidants have been reported to attenuate inflam-
matory response, insulin resistance, and diabetes devel-
opment [15-17]. One promising antioxidant is flaxseed.
The active ingredient of flaxseed (lignan, secoisolaricire-
sinol diglucoside (SDG)) has significant antioxidant
effects by inhibiting DNA scissions and lipid peroxida-
tion and decreaseing ROS [18-21]. Flaxseed also has sig-
nificant anti-inflammatory effects [22-26]. Flaxseed oil,
flaxseed lignan, or flaxseed supplementation significantly
decreased serum TNF-a, IL-1 b, IL-6, CRP, glucose, or
glycosylated haemoglobin concentrations or increased
insulin sensitivity in humans [25-30]. Dietary flaxseed,
flaxseed oil, or flaxseed lignan decreased inflammation,
oxidative lung damages, lipid peroxidation, or hyperin-
sulinemia in animals [24,31-33].
Flaxseed is safe and readily available for dietary con-
sumption that positively affects inflammation, glycemic
control, and oxidative stress. The current study was
conducted to determine the mechanism(s) by which
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flaxseed offers the protection against insulin resistance
and inflammation via regulation of oxidative stress. It
was hypothesized that flaxseed supplementation will
decrease oxidative stress, thus reducing inflammation
biomarkers and insulin resistance. The effects of flax-
seed on oxidative stress, insulin resistance, and inflam-
mation were reported in this article.
Methods
The present study was approved by the Institutional
Review Board at North Dakota State University. Written
consent was obtained from all participants before the
initiation of the study.
Participant Selection
Potential participants who were overweight, hyperten-
sive, and with a family history of diabetes were screened
for impaired fasting plasma glucose. Following a positive
impaired fasting plasma glucose (>100 mg/dL), an oral
glucose tolerance test (OGTT) was completed. Indivi-
duals included into the study had fasting plasma glucose
concentration between 100-125 mg/dL, and following a
100 g oral glucose load, had 2-hour plasma glucose of
greater than 140 mg/dL but less than 199 mg/dL. The
dose of 100 g oral glucose was used following current
diagnostic test guidelines of Sanford Health Laboratory
in consideration of obesity and increased body surface
area to be covered by glucose solution [34]. General
health status including vitamin/mineral/herbal supple-
mentation and medication intake was determined by
health questionnaires before and at the end of the study.
Individuals excluded from the study included: people (1)
on prescribed oral hypoglycemic medication or insulin
injection; (2) had any diagnosed illness other than
controlled hypertension or impaired glucose tolerance;
or (3) allergic to either flaxseed or wheat. Thirty
three people were screened and 11 qualified for study
participation.
Design and Treatments
A randomized crossover research design was used for
the study. Eleven participants were randomly assigned
into one of two groups: flaxseed or wheat bran supple-
mentation group. Participants received a daily allotment
of either 40 g of wheat bran or flaxseed in form of
ground grain or bread for 12 weeks. Participants were
instructed to incorporate the supplement in their daily
meals using a method of their choice. Following a 4-
week washout period of no supplements, participants
received the alternate supplement (either flaxseed or
wheat bran) for another 12 weeks. The ingredients in
the bread were adjusted to provide similar calories in
both supplemental breads. The bread was baked at a
local bakery. Before entering the study, participants
were instructed to substitute the study supplement for
some of their usual carbohydrate and fat consumed at
the meal so that no additional calories would be con-
sumed. Participants were requested to keep the supple-
ment in the freezer to maintain freshness. Participants
were also asked to record the amount eaten and to
return leftover supplements to the investigators. The
collected leftover supplements were weighed by the
investigators to check dietary compliance. Nutrient com-
positions of wheat bran bread or flaxseed bread were
analyzed using Food Processor software (version 10.5.1,
ESHA Research, Salem, OR).
A health questionnaire that included birth date, cur-
rent health conditions, medication use, vitamin, mineral,
or herbal supplement use, and exercise practices was
completed at the screening. A follow-up health ques-
tionnaire was completed at the end of the study to
determine if any changes had occurred in the partici-
pant’s health or exercise practices. Each participant’s
height (without shoes) was measured during the screen-
ing test. Using a balance beam scale, each participant
was weighed at the screening, at the beginning and end
of each supplementation. BMI was calculated using the
equation BMI = weight (kg)/height2 (m2). Waist circum-
ference was measured using a measuring tape. The mea-
suring tape was placed around the abdomen at the level
of the iliac crest and took the reading at the end of a
normal expiration [35]. The Block Brief 2000 Food
Questionnaire, a validated self-administered 66-item
semi-quantitative food frequency questionnaire [36], was
administered at the beginning of each supplementation.
Blood Sample Collection and Laboratory Assays
After a 12-hour fast, participants had venous blood
drawn. Samples were collected before and after each 12-
week supplementation. Fasting plasma glucose concen-
tration was measured by Sanford Health; the result was
reported elsewhere [37]. Plasma insulin concentration
was measured using an enzyme-linked immunosorbent
assay (ELISA) kit (Alpco Co., Salem, NH). Plasma TNF-
a (Invitrogen, Carlsbad, CA), IL-6 (Cayman Chemical,
Ann Arbor, MI), and high sensitivity (hs)-CRP (Bio-
Check, Inc., Burlingame, CA) concentrations were mea-
sured using ELISA kits. Thiobaribituric acid reactive
substance (TBARS) was measured to estimate oxidative
stress using a kit (ZeptoMetrix Co, Buffalo, NY). Home-
ostasis model assessment (HOMA-IR) was used to esti-
mate insulin resistance. The following formula was used
for HOMA-IR calculation: (insulin [pmol/L] × glucose
[mmol/L]/22.5) [38].
Statistical Analysis
SAS software (version 9.1; SAS, Cary, NC) was used for
data analysis. Data were tested for normality by a
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univariate test and homogeneity of variances by a t-test.
The effect of treatment groups (between wheat bran and
flaxseed groups) on plasma insulin, HOMA-IR, TBARS,
TNF-a, IL-6, and hs-CRP concentrations was assessed
using two sample t-tests whereas the effect of the 12
weeks of supplementation (within each supplementation
group) on plasma insulin, HOMA-IR, TBARS, TNF-a,
IL-6, and hs-CRP concentrations was assessed using
paired t-tests. Pearson correlation coefficients were used
to assess relationships among the test variables. A type I
error rate of 0.05 was used to assess significance for all
statistical tests.
Results
A total of eleven people initially participated in the
study. Four participants dropped out: two after first
blood sample collection and another two after the third
blood sample collection. The first two participants with-
drew from the study due to personal reasons unrelated
to the study; the latter two participants dropped out of
the study because they did not like the wheat bran sup-
plement. The two who dropped out during the first
phase of supplementation were excluded from the data
analysis; however, the participants who dropped out
during the second phase of supplementation were
included in the data analysis. The overall compliance
rate with dietary supplements was >95%. Supplemental
bread that contained 40 g of either ground flaxseed or
wheat bran, provided 453 kcal and 398 kcal, respectively
[37]. Table 1 shows the nutrient composition of supple-
mental bread.
The average age of the participants was 54.7 ± 6.6
years. Of the nine participants, four were male and five
were female. Participants reported no change in dietary
intake, health status including inflammatory status, or
exercise habits throughout the study. All participants
were nonsmokers and reported exercising for 30 min-
utes or more per day, 3-5 days per week. Six partici-
pants reported taking multivitamins; two participants
reported taking calcium/magnesium supplements; and
one participant reported taking a vitamin E supplement.
Body weight and BMI were not significantly different
compared to the baseline, nor between treatment
groups. The average body weight was 96.2 ± 18.9 vs.
92.2 ± 20.4 (kg), flaxseed group; 94.7 ± 20.0 vs. 95.2 ±
20.3 (kg), wheat bran group at the baseline and end of
the study, respectively. The average BMI was 32.4 ± 8.2
vs. 30.3 ± 5.5 (kg/m2), flaxseed group; 32.0 ± 8.3 vs. 32.4
± 8.3 (kg/m2), wheat bran group at the baseline and end
of the study, respectively. No significant relationships
between weight change and glucose, insulin, HOMA-IR,
or inflammatory biomarkers were found. The waist cir-
cumference did not change significantly. The average
waist circumference was 106.9 ± 13.5 vs. 105.9 ± 12.7
(cm), flaxseed group; 108.7 ± 12.2 vs. 106.7 ± 13.5 (cm),
wheat bran group at the baseline and end of the study,
respectively.
Based on a self-administered 66-item semi-quantitative
food frequency questionnaire, no significant differences
were observed in mean daily energy and nutrient intakes
between each supplementation. At the beginning of the
first supplementation, mean energy intake was 1875 ±
798 kcal/d, with 17%, 38%, and 45% coming from pro-
tein, fat and carbohydrates, respectively. At the begin-
ning of the second supplementation, mean energy intake
was 2038 ± 973 kcal/d, with 17%, 37%, and 46% coming
from protein, fat and carbohydrates, respectively. Vita-
mins C and E and beta carotene, antioxidants, con-
sumed as food were not significantly different among
the participants. Software limitations prevented analysis
of the dietary intake of a-linolenic acid and insoluble
and soluble fiber.
Flaxseed supplementation significantly reduced fasting
plasma glucose concentration compared to the baseline
(0 wk) and compared to the wheat bran supplementation:
5.92 ± 0.31 vs 4.79 ± 0.17 (mmol/L), flaxseed group; 5.67
± 0.14 vs. 5.73 ± 0.35 (mmol/L), wheat bran group [37].
Flaxseed supplementation did not significantly change
fasting plasma insulin concentration (Figure 1). However,
12 weeks of wheat bran supplementation significantly
reduced plasma insulin concentration compared to
baseline (p = 0.026, Figure 1).
When estimating insulin resistance using HOMA-IR
[38], flaxseed supplementation significantly decreased an
HOMA-IR index (34.7%) compared to the baseline.
Wheat bran supplementation did not significantly
change an HOMA-IR index (Figure 2). Moreover, flax-
seed supplementation decreased plasma TBARS concen-
tration compared to baseline (Figure 3). Significant
relationships were found between HOMA-IR and insulin
Table 1 Composition of daily supplemental flaxseed
bread and wheat bran bread*
Measures Flaxseed Wheat bran
Energy (kcal/d) 453 398
Carbohydrate (g/d) 72.2 83.4
Fiber (g/d) 13.1 18.6
Protein (g/d) 16.8 14.8
Fat (g/d) 16.4 6.0
Saturated fatty acids (g/d) 6.6 0.8
Monounsaturated fatty acids (g/d) 4.5 1.3
Polyunsaturated fatty acids (g/d) 5.0 3.2
Omega 3 fatty acid (g/d) 8.4 0.1
Omega 6 fatty acid (g/d) 2.5 2.9
*Composition of flaxseed and wheat bran bread was reported previously [37].
Composition of daily supplemental flaxseed bread and wheat bran bread are
based on ingredient analysis using Food Processor Software (version 10.5.1,
ESHA Research, Salem, OR).
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(r = 0.89, p < 0.0001) and HOMA-IR and glucose (r =
0.66, p < 0.0001).
The inflammation biomarkers, TNF-a, IL-6, and hs-CRP
did not change significantly following 12 weeks of flaxseed
or wheat bran supplementation (Table 2). However,
positive relationships between plasma glucose and TBRAS
(r = 0.39, p = 0.034), TBARS and TNF-a (r = 0.57, p =
0.0011), TBARS and insulin (r = 0.52, p = 0.0035), and
TBARS and HOMA-IR (r = 0.62, p = 0.0003) were found.
Discussion
The current study was intended to determine, if the
flaxseed supplementation would have an effect on insu-
lin resistance via regulation of oxidative stress in obese
glucose intolerant people. The current study found that
flaxseed supplementation decreased insulin resistance.
Although the plasma insulin concentration did not
change significantly, an HOMA-IR index significantly
decreased, suggesting a decrease in insulin resistance or
decreased glucose concentration following flaxseed sup-
plementation. A highly significant positive relationship
(r = 0.89) between HOMA-IR and insulin indicates that
the decreased HOMA-IR is more closely related to insu-
lin concentration than glucose concentration. Decreased
HOMA-IR following flaxseed lignan or flaxseed supple-
mentation without significant changes in insulin concen-
tration has also been reported by others [28,30]. No
significant changes in plasma insulin concentration fol-
lowing flaxseed supplementation might be related to
small sample sizes in the current study which warrant
the need of future study with a larger sample size.
In the present study, flaxseed supplementation showed
a beneficial effect on oxidative stress as determined
by TBARS. Flaxseed supplementation significantly
decreased TBARS concentration which suggests decreased
lipid peroxidation in these participants and an antioxidant
activity of flaxseed.
In the present study, TNF-a, IL-6, and CRP remained
within normal ranges. The results suggest that these
*
Figure 1 Fasting plasma insulin concentrations before and
after each supplementation. Data are presented as mean ±
standard error, n = 7-9; Statistical significance level was set at 0.05.
*Significantly decreased after 12 weeks of wheat bran
supplementation compared to the baseline, p = 0.026. No
significant change in plasma insulin concentration after 12 weeks of
flaxseed supplementation. No significant differences in plasma
insulin concentration between flaxseed and wheat bran
supplementation groups
Figure 2 HOMA-IR index before and after each supplementation.
Data are presented as mean ± standard error, n = 7-9; Statistical
significance level was set at 0.05. *Significantly decreased after 12
weeks of flaxseed supplementation compared to the baseline, p =
0.0382. No significant change in HOMA-IR after 12 weeks of wheat
bran supplementation. No significant differences in HOMA-IR
between flaxseed and wheat bran supplementation groups
Figure 3 Plasma TBARS concentrations before and after each
supplementation1. 1TBARS is an indicator for lipid peroxidation,
and it is measured in MDA equivalents. Data are presented as mean
± standard error, n = 7-9; Statistical significance level was set at
0.05. *Significantly decreased after 12 weeks of flaxseed
supplementation compared to the baseline, p = 0.0215. No
significant change in plasma TBARS concentration after 12 weeks of
wheat bran supplementation. No significant differences in plasma
TBARS concentration between flaxseed and wheat bran
supplementation groups
Table 2 Inflammation biomarker changes over the course
of the experiment1
Baseline After 12 weeks
Flaxseed Wheat Bran Flaxseed Wheat Bran
IL-6 (pg/mL) 3.2 ± 0.6 3.1 ± 0.5 3.2 ± 0.5 3.6 ± 0.8
TNF-a (pg/mL) 0.9 ± 0.4 0.6 ± 0.5 0.8 ± 0.5 0.7 ± 0.6
hs-CRP (mg/L) 3.6 ± 1.7 4.6 ± 2.1 3.9 ± 0.9 7.2 ± 5.5
1 All values are mean ± standard deviation; n = 7-9; Statistical significance
level was set at 0.05
The inflammation biomarkers, IL-6, TNF-a, and hs-CRP did not change
significantly following 12 weeks of flaxseed or wheat bran supplementation.
No significant difference in IL-6, TNF-a, and hs-CRP between flaxseed and
wheat bran supplementation groups
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obese participants did not have low grade systemic
inflammation, but these participants are classified as a
high cardiovascular disease risk group [39]. Studies
show that CRP concentration remained the same follow-
ing flaxseed or flaxseed lignan supplementation while
CRP concentration in the control supplementation
group increased [29,30,40,41]. A similar result was
found in the present study. While CRP concentration in
flaxseed supplementation group remained the same as
the baseline, it increased following wheat bran (control)
supplementation. Although flaxseed oil has been
reported to significantly decrease serum TNF-a or IL-6
in humans [25,26], no significant changes were found in
TNF-a or IL-6 following flaxseed or flaxseed lignan sup-
plementation [28-30,40] which is in agreement with the
findings of the present study.
Increased glucose oxidation and NADPH oxidase
activity secondary to hyperglycemia and obesity increase
ROS generation [42,43]. Participants in the present
study were hyperglycemic and obese, and they had nor-
mal TNF-a and IL-6 concentrations which suggest that
the participants might have had increased oxidative
stress secondary to high plasma glucose concentrations
and their obesity not secondary to inflammation.
Increased oxidative stress may suppress insulin receptor
activation or decrease the translocation of GLUT4 on
the cell membrane [44]. It was found that antioxidants
increase glucose disposal via increased translocation of
GLUT 4 on the cell membrane and increase basal glu-
cose uptake via redistribution of GLUT 1 [44,45].
Although GLUT expression or cellular glucose uptake
was not measured in the present study, SDG treatment
increased basal glucose uptake in human RBCs in our
previous study [46].
Increased ROS, especially hydroxyl radicals increase
TBARS concentration. TBARS is an indicator for lipid
peroxidation, and it is measured in malondialdehyde
(MDA) equivalents. Decreased TBARS concentration
following flaxseed supplementation indicates decreased
lipid peroxidation. SDG in flaxseed decreases lipid per-
oxidation by scavenging hydroxyl radical [47,48].
Reduced lipid peroxidation may have maintained cell
membrane integrity keeping insulin receptor intact, thus
may have contributed to increased glucose disposal. The
positive relationships seen between TBARS and insulin
and TBARS and HOMA-IR in the present study are in
agreement with other study findings that increased ROS
triggers insulin resistance [49-52].
Weight loss improves insulin resistance by increasing
insulin sensitivity [53]. However, no significant weight
changes in these participants suggest that decreased
HOMA-IR index is not related to weight loss. Our
results support that high glucose concentrations increase
oxidative stress [54] as shown increased TBARS. As seen
by others [51] the positive relationships between TBARS
and HOMA-IR indicate that increased oxidative stress
may have increased insulin resistance in these obese
participants. Moreover, positive relationships between
TBARS and TNF-a concentrations found in this study
support that increased oxidative stress increases
pro-inflammatory cytokines [55].
Soluble and insoluble fiber in flaxseed shown to
improve glycemic control [56], and is inversely related
to CRP concentrations [57]. The current study did not
evaluate the fiber effects on the insulin resistance and
inflammation biomarkers. However, as discussed in else-
where [37], the wheat bran supplementation provided
higher concentration of dietary fiber (18.6 g/d) com-
pared to flaxseed (13.1 g/d) in the current study. In
addition, daily dietary fiber intake was not different
between flaxseed and wheat bran groups [37]. No signif-
icant changes in inflammation biomarkers or insulin
resistance indicators (glucose or HOMA-IR) following
wheat bran supplementation indicate that the antioxi-
dant activity of flaxseed or other bioactive component of
flaxseed such as a-liniolenic acid might have attributed
to decreased insulin resistance rather than dietary fiber.
Decreased insulin resistance might be attributed to lig-
nan via its antioxidant activity of flaxseed in these obese
participants. However, the present study was not able to
identify the direct role of lignan in insulin resistance
due to a high a-linolenic acid content in whole flaxseed.
Therefore, further study is needed to determine the
effects of flaxseed lignan on insulin resistance and
peripheral glucose uptake to identify the mechanism(s)
of decreased insulin resistance. Although flaxseed
decreased HOMA-IR and TBARS, but none of the
changes in TBARS, insulin, and HOMA-IR between
flaxseed and wheat bran supplementation groups was
significantly different. No significant difference in
HOMA-IR, insulin, and TBARS between flaxseed and
wheat bran supplementation also supports the need of
study using flaxseed lignan to further determine the
mechanism(s) of decreased insulin resistance via antioxi-
dant activity of flaxseed.
The present results indicate that obese participants were
glucose intolerant without low grade systemic inflamma-
tion. Since these participants did not have an identified
inflammatory condition, flaxseed supplementation may
have not affected these inflammation biomarkers. If these
participants had systemic inflammation secondary to obe-
sity or impaired glucose tolerance, flaxseed effects on
inflammation may have been seen. This also suggests the
need of future study using either animal models with
inflammation or people with systemic inflammation to
determine flaxseed effects on inflammation.
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Conclusions
In conclusion, it was hypothesized that an antioxidant
(lignan) in flaxseed would decrease ROS generation
which downregulates TNF-a and IL-6 production.
Therefore, the bioactive component of flaxseed, lignan,
would decrease inflammation and insulin resistance.
Although no statistical differences were seen in inflam-
mation biomarkers following flaxseed supplementation,
the positive relationship between TBARS and TNF-a
suggests that increased oxidative stress would increase
TNF-a. Moreover, the positive relationship between
TBARS and HOMA-IR suggests that increased oxidative
stress increased insulin resistance. Although flaxseed
supplementation decreased HOMA-IR and TBRAS inde-
pendently, these variables were not significantly different
compared to wheat bran supplementation. No signifi-
cant difference in HOMA-IR and TABRS between flax-
seed and wheat bran supplementation groups weakly
supports a hypothesis of the current study: flaxseed sup-
plementation will decrease oxidative stress, thus redu-
cing inflammation biomarkers and insulin resistance. A
small sample size and a cumulative effect of a-linolenic
acid and/or fiber in the flaxseed might have caused non-
significant differences in HOMA-IR and TBARS
between flaxseed and wheat bran supplementation
groups. Therefore, further study is needed to determine
the role of antioxidant activity of flaxseed in insulin
resistance using flaxseed lignan and with a larger sample
size.
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